[go: up one dir, main page]

WO2019039781A2 - Nouveau bactériophage d'aeromonas salmonicida aer-sap-2 et son utilisation dans l'inhibition de la prolifération d'aeromonas salmonicida - Google Patents

Nouveau bactériophage d'aeromonas salmonicida aer-sap-2 et son utilisation dans l'inhibition de la prolifération d'aeromonas salmonicida Download PDF

Info

Publication number
WO2019039781A2
WO2019039781A2 PCT/KR2018/009229 KR2018009229W WO2019039781A2 WO 2019039781 A2 WO2019039781 A2 WO 2019039781A2 KR 2018009229 W KR2018009229 W KR 2018009229W WO 2019039781 A2 WO2019039781 A2 WO 2019039781A2
Authority
WO
WIPO (PCT)
Prior art keywords
bacteriophage
eromonas
sap
bacteria
aer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/009229
Other languages
English (en)
Korean (ko)
Other versions
WO2019039781A3 (fr
Inventor
윤성준
전수연
권안성
이호진
강상현
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intron Biotechnology Inc
Original Assignee
Intron Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intron Biotechnology Inc filed Critical Intron Biotechnology Inc
Publication of WO2019039781A2 publication Critical patent/WO2019039781A2/fr
Publication of WO2019039781A3 publication Critical patent/WO2019039781A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae

Definitions

  • the present invention relates to a bacteriophage isolated from nature capable of killing eromonas salmonididae by infection with eromonas salmonididae, and a composition containing the same as an effective ingredient to prevent diseases caused by eromonas salmonididae Characterized in that it has the ability to kill eromonas salmonididae and has the genome of SEQ ID NO: 1, characterized in that the mio viridis versus bacteriophage Aer-SAP -2 (Accession No. KCTC 12909BP), and a method for preventing or treating a disease caused by eromonas salmonidia bacteria using the composition comprising the bacteriophage as an active ingredient.
  • Aeromonas salmonicida belonging to Aeromonadaceae , is a tuberous anaerobic gram-negative bacterium and is a non-invasive mononuclear bacterium that causes serious diseases such as salmonid and salmonid fish such as salmon and rainbow trout. Is known as a causative organism.
  • Eromonas salmonidida has a homogeneous serotype and is known to have a thermostable, O antigen.
  • Eromonas salmonidida which has a thermostable bacterial antigen, is pathogenic to sepsis and is known to cause systemic infection especially when it has antigen group O3.
  • Eromonas salmonidida may cause extensive bacterial septicemia or furunculosis in fish and may cause massive mortality in severe cases and cause significant economic loss in the fish industry . Therefore, it is urgent to develop a method that can be used to prevent the infection of eromonas salmonidida and further to treat the infection.
  • Bacteriophage is a very small microorganism that infects bacteria, usually called phage.
  • the bacteriophage has the ability to kill bacterial cells by infecting the bacteria inside the cells after infecting the bacteria and destroying the cell wall of the host bacteria when the progeny bacteriophages come out of the bacteria after the proliferation.
  • the bacterium infection method of bacteriophage is highly specific, and the types of bacteriophages that can infect specific bacteria are limited to some.
  • certain bacteriophages can infect only a specific category of bacteria, and thus certain bacteriophages can provide an antibacterial effect only for certain bacteria. Due to the bacterium specificity of these bacteriophages, bacteriophage provides an antimicrobial effect only on the bacteria of interest and does not affect the environment or bacteria in the environment. Conventional antibiotics, which have been widely used for bacterial treatment, have simultaneously influenced several kinds of bacteria. This has caused problems such as environmental contamination and disturbance of normal flora of animals. In contrast, bacteriophages operate only on specific bacteria, so that the use of bacteriophages does not cause a total disturbance in the body. Therefore, the use of bacteriophage is very safe as compared with the use of antibiotics, and the possibility of side effects caused by use is relatively low.
  • Bacteriophage is a British bacteriologist Twort 1915 became discovered while conducting research on Staphylococcus aureus (Micrococcus) melting the colonies are transparent by any developer.
  • the French bacteriologist d'Herelle discovered that there was an effect of dissolving Shigella dysenteriae in the filtrate of heterozygous patients.
  • bacteriophage Due to the special ability to kill bacteria, bacteriophage has been expected to be effective as a countermeasure against bacterial infection since its discovery.
  • the discovery of penicillin by Fleming the spread of antibiotics has become common, and studies of bacteriophage have been limited to some Eastern European countries and the Soviet Union.
  • the limitations of existing antibiotics have appeared due to the increase of antibiotic resistant bacteria, and bacteriophages have been attracting attention as an anti - bacterial agent due to the possibility of development as a substitute for existing antibiotics.
  • bacteriophages are highly specific for bacteria. Because of the high specificity of these bacteriophages to bacteria, bacteriophages often exhibit antibacterial effects only on some strains, even if they belong to the same species (Species). In addition, the intensity of the antibacterial activity of bacteriophages exhibited according to the target bacterial strain may be different. For this reason, it is necessary to secure various kinds of useful bacteriophages in order to obtain an effective control method for a certain kind of bacteria.
  • the present inventors have developed a composition that can be utilized for the prevention or treatment of diseases caused by eromonas salmonididae using bacteriophages isolated from nature capable of killing eromonas salmonididae Further, after trying to develop a method for preventing or treating a disease caused by eromonas salmonididae by using this composition, a bacteriophage suitable for this is separated from nature, and the separated bacteriophage is distinguished from other bacteriophages The present inventors have developed a composition comprising the bacteriophage as an active ingredient after securing the sequence information of the genome so as to be able to construct the erythromycin, To complete the present invention Respectively.
  • an object of the present invention is to provide a Myoviridae bacteriophage Aer-SAP ( hereinafter referred to as " bacteriophage ") isolated from nature, which has the ability to specifically kill eromonas salmonididae and has a genome represented by SEQ ID NO: -2 (accession number KCTC 12909BP).
  • the present invention provides a method for preventing or treating a disease caused by eromonas salmonidosis using a composition that can be used for the purpose of preventing or treating diseases caused by Shido bacteria.
  • the present invention relates to a microorganism isolated from nature, which has the ability to specifically kill eromonas salmonididae and has a genome represented by SEQ ID NO: 1, and a microorganism isolated from bacteriophage Aer-SAP-2 (Accession No. KCTC 12909BP), and a method for preventing or treating a disease caused by eromonas salmonidia bacteria using the composition containing the same as an active ingredient.
  • Bacteriophage Aer-SAP-2 has been deposited with the Korean Resource Center for Biotechnology (Accession No. KCTC 12909BP) on Sep. 22, 2015, after being separated by the present inventors.
  • the present invention also provides a bathing agent and a feed additive comprising bacteriophage Aer-SAP-2, which can be utilized for preventing or treating diseases caused by eromonas salmonidia, as an active ingredient.
  • the composition of the present invention can be utilized for the purpose of preventing or treating diseases caused by eromonas salmonidia.
  • &quot prevent " or " prophylaxis " refer to (i) prevention of infection of eromonas salmonidia; And (ii) inhibiting development into a disease caused by eromonas salmonididae infection.
  • " treatment " or " treatment " refers to (i) inhibition of a disease caused by eromonas salmonidosis; And (ii) alleviating the pathological condition of the disease caused by eromonas salmonididae.
  • the terms “separate”, “isolated”, or “separated” refer to the separation of bacteriophages from the natural state using various experimental techniques and the securing of features that can identify the bacteriophages of the invention by distinguishing them from other bacteriophages
  • the present invention also includes propagating the bacteriophage of the present invention industrially so as to utilize it by biotechnology.
  • the pharmaceutically acceptable carriers to be contained in the composition of the present invention are those conventionally used in the formulation and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate , Microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, no.
  • the composition of the present invention may further contain lubricants, wetting agents, sweeteners, flavors, emulsifiers, suspending agents, preservatives, etc. in addition to the above components.
  • the composition of the present invention contains bacteriophage Aer-SAP-2 as an active ingredient.
  • the bacteriophage Aer-SAP-2 contained therein is contained at a concentration of 1 ⁇ 10 1 pfu / ml to 1 ⁇ 10 30 pfu / ml or 1 ⁇ 10 1 pfu / g to 1 ⁇ 10 30 pfu / g, 10 4 pfu / ml to 1 x 10 15 pfu / ml or 1 x 10 4 pfu / g to 1 x 10 15 pfu / g.
  • composition of the present invention may be prepared in a unit dose form by being formulated using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs. It may be manufactured by inserting it into a multi-capacity container.
  • the formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
  • the composition of the present invention may be embodied as a bathing agent and a feed additive, depending on the manner of application, but not limited thereto.
  • Bacteriophages capable of providing an antimicrobial activity against other bacterial species may be added to the composition of the present invention in order to increase efficiency in such a utilization purpose.
  • other types of bacteriophages having antimicrobial activity against eromonas salmonididae may also be added. Even the bacteriophage having antimicrobial activity against eromonas salmonidida may differ in terms of the strength of antimicrobial activity or the range of antimicrobial activity, so that a proper combination thereof can maximize its effect.
  • the method for preventing or treating a disease caused by eromonas salmonidia bacteria using the composition comprising the bacteriophage Aer-SAP-2 of the present invention as an active ingredient is more effective than the method based on conventional antibiotics, It is possible to provide an advantage that the specificity to Shidacia is very high. This means that it can be used for the purpose of preventing or treating diseases caused by eromonas salmonidida without affecting other useful microbes, and means that there are very few side effects from the use thereof. Generally, when antibiotics are used, common endophytic bacteria are also harmed, resulting in a decrease in immunity of animals and various side effects due to their use.
  • bacteriophages have a strong antimicrobial activity against bacterial species capable of exhibiting antimicrobial activity even in the case of bacteriophages exhibiting antimicrobial activity.
  • Bacteriophagus The range in which the antibacterial activity is exerted.
  • bacteriophages can exhibit antibacterial activity against some bacterial strains belonging to the same species. In other words, even if belonging to the same bacterium species, there may be differences in susceptibility to bacteriophages depending on the individual bacterium. Therefore, the present invention provides a method for producing a bacteriophage having different antibacterial activity against erythromycin salmonidic acid bacteria Effect can be provided. This provides a big difference in its effectiveness when used in industrial settings.
  • Figure 1 is an electron micrograph of bacteriophage Aer-SAP-2.
  • Figure 2 shows the results of experiments showing the ability of bacteriophage Aer-SAP-2 to eromonas salmonidida to kill. Based on the center line of the plate medium, only the buffer containing no bacteriophage Aer-SAP-2 is dispensed on the left side, and the solution containing the bacteriophage Aer-SAP-2 is dispensed on the right side. The transparent part observed on the right is the result of the lysis of bacteria to be tested by the action of bacteriophage Aer-SAP-2.
  • Example One Eromonas You can live. Isolation of bacteriophage that can kill bacteria
  • erotic Pseudomonas live monitor let a TSB inoculated with the bacteria in the 1 / 1,000 the ratio (T ryptic S oy B roth) medium (Casein Digest, 17 g / L; Soy bean Digest, 3 g / L; Dipeptidium phosphate, 2.5 g / L) were added together and then shake-cultured at 25 DEG C for 3-4 hours. After incubation, the supernatant was recovered by centrifugation at 8,000 rpm for 20 minutes.
  • T ryptic S oy B roth Casein Digest, 17 g / L
  • Soy bean Digest 3 g / L
  • Dipeptidium phosphate 2.5 g / L
  • the recovered supernatant was inoculated with eromonas salmonidida at a ratio of 1 / 1,000 and then shake-cultured again at 25 DEG C for 3-4 hours.
  • this procedure was repeated five times in total so that the number of bacteriophages could be sufficiently increased.
  • the culture was centrifuged at 8,000 rpm for 20 minutes. After centrifugation, the recovered supernatant was filtered using a 0.45 ⁇ m filter. Through a conventional spot assay using the thus obtained filtrate, the presence of bacteriophage capable of killing eromonas salmonidia was examined.
  • the above drop test was carried out as follows.
  • the TSB medium was inoculated with eromonas salmonidida at a ratio of 1 / 1,000, and then cultured with shaking at 25 DEG C overnight.
  • TSA T ryptic S oy A gar
  • plate medium Casein Digest, 15 g / L; Soy bean digest, 5 g / L; NaCl , 5 g / L; agar, 15 g / L.
  • the smear medium was allowed to stand in a clean bench for about 30 minutes to allow the smear solution to dry.
  • Pure bacteriophage was isolated by using the filtrate which showed the existence of bacteriophage having killing ability against eromonas salmonidida.
  • a usual plaque assay was used for the separation of pure bacteriophage. To explain this in detail, one of the broths formed in the leavening assay was recovered using a sterilized tip, and then added to the culture solution of eromonas salmonidis, followed by incubation at 25 ° C. for 4-5 hours. After incubation, supernatant was obtained by centrifugation at 8,000 rpm for 20 minutes.
  • the culture medium of eromonas salmonidicum was added to the obtained supernatant in a volume of one-fifth of the volume, followed by further incubation at 25 ° C for 4-5 hours. This procedure was performed at least 5 times to increase the number of bacteriophages, and finally the supernatant was obtained by centrifugation at 8,000 rpm for 20 minutes. The obtained supernatant was used for the analysis of the washing solution. Since the separation of the pure bacteriophage is not normally achieved by only one step of the above procedure, the former step is repeated again by using the formed agitation blank. This procedure was repeated at least five times to obtain a solution containing pure bacteriophage.
  • the solution containing pure bacteriophage identified in this way was subjected to the following purification procedure.
  • the culture of eromonas salmonidicum was added in a volume of one-half of the total volume of the solution, followed by further incubation for 4-5 hours. After incubation, supernatant was obtained by centrifugation at 8,000 rpm for 20 minutes. This process was repeated five times in total to obtain a solution containing a sufficient number of bacteriophages.
  • the supernatant obtained by the final centrifugation was filtered using a 0.45 ⁇ m filter, and then a conventional polyethylene glycol (PEG) precipitation process was performed.
  • PEG polyethylene glycol
  • PEG and NaCl were added to 100 ml of the filtrate to make 10% PEG 8000 / 0.5 M NaCl, and the mixture was allowed to stand at 4 ° C for 2-3 hours, followed by centrifugation at 8,000 rpm for 30 minutes to obtain a bacteriophage precipitate .
  • precipitate bacteriophage buffer Buffer; 10 mM Tris-HCl , 10 mM MgSO 4, 0.1% Gelatin, pH 8.0
  • This is called a bacteriophage suspension or bacteriophage solution.
  • the purified bacteriophage was named as Bacteriophage Aer-SAP-2 and deposited on September 22, 2015 with the BRC (Korea Research Institute of Bioscience and Biotechnology) (Accession No. KCTC 12909BP ).
  • Example 2 Bacteriophage Aer - SAP -2 genome sequencing and genome sequencing
  • the genome of bacteriophage Aer-SAP-2 was isolated as follows.
  • the bacteriophage suspension obtained by the same method as in Example 1 was used.
  • 200 U of DNase I and 200 A of RNase A were added to 10 ml of the bacteriophage suspension, and the mixture was left at 37 ° C for 30 minutes.
  • 500 ⁇ l of 0.5 M ethylenediaminetetraacetic acid (EDTA) was added to remove DNase I and RNase A activity, and the mixture was allowed to stand for another 10 minutes.
  • EDTA ethylenediaminetetraacetic acid
  • the upper layer was taken out of the separated layers, 1.5 parts by volume of isopropyl alcohol was added thereto, and the mixture was centrifuged at 13,000 rpm for 10 minutes The dielectric was precipitated. After the precipitate was collected, 70% ethanol was added to the precipitate, and the precipitate was further washed by centrifugation at 13,000 rpm for 10 minutes. The washed precipitate was recovered, vacuum dried and dissolved in 100 ⁇ l of water. The above procedure was repeated to secure a large amount of the genome of bacteriophage Aer-SAP-2.
  • the genome thus obtained was subjected to next generation sequencing analysis using the illumina Mi-Seq instrument in Macrogen, and the genome sequence information of bacteriophage Aer-SAP-2 was obtained.
  • the finally analyzed bacteriophage Aer-SAP-2 genome has a size of 53,870 bp and the entire genomic sequence is shown in SEQ ID NO: 1.
  • bacteriophage Aer-SAP-2 is a new bacteriophage different from the previously reported bacteriophages.
  • bacteriophage Aer-SAP-2 can provide different antimicrobial effects from other bacteriophages reported from the fact that the different kinds of bacteriophages usually provide different antimicrobial power and antimicrobial range there was.
  • Example 3 Bacteriophage Aer - SAP -2 of Eromonas You can live. For bacteria Destructiveness Research
  • the ability of the isolated bacteriophage Aer-SAP-2 to eromonas salmonidida was investigated.
  • the extinction ability was investigated by examining whether or not a transparent ring was formed through the drip test as described in Example 1.
  • the Eromonas salmonidida strains used for the study of the killing activity were 17 weeks in total, which were either purchased through the strain bank or isolated by the present inventors and identified as Eromonas salmonididae.
  • Bacteriophage Aer-SAP-2 has an ability to kill for 15 weeks in total, including KEMB4-337 strain (KEMB: Korea Environmental Microorganisms Bank, Environmental Microbial Bank), among the 17 weeks of eromonas salmonidia there was. Representative experimental results are shown in Fig.
  • the bacteriophage Aer-SAP-2 has excellent killing ability against eromonas salmonidida and can exert antibacterial effect against many eromonas salmonidia strains. This means that bacteriophage Aer-SAP-2 can be used as an active ingredient of a composition for the prevention or treatment of diseases caused by eromonas salmonidosis.
  • Example 4 Bacteriophage Aer - SAP -2 of Eromonas You can live. For prevention of fungal infection Experimental Example
  • the bacteriophage Aer-SAP-2 of the present invention not only inhibits the growth of eromonas salmonidicum but also has the ability to kill eromonas salmonidosis. From this, it is confirmed that bacteriophage Aer-SAP- -2 could be used as an effective ingredient of a composition for the prevention of diseases caused by eromonas salmonididae.
  • Example 5 Bacteriophage Aer - SAP -2 Eromonas You can live. Bacterium-induced Preventive Animal Test for Disease
  • Rainbow trout (average weight: 23.4 g, average length: 15.8 cm) was divided into two groups of 20 rats and separated for 14 days in a water tank. The ambient environment of the water tank was controlled, and the temperature of the laboratory with the water tank was kept constant. Feeds containing 1 ⁇ 10 8 pfu / g of bacteriophage Aer-SAP-2 were fed to rainbow trout in the experimental group (bacteriophage-treated group) from the start of the experiment to the experimental period according to a conventional feed feeding method. On the other hand, the rainbow trout of the control group (bacteriophage MIT) received feeds of the same composition without bacteriophage Aer-SAP-2 in the same manner.
  • Body size ulcer size measurement (average) US score (mean) date D9 D10 D11 D12 D13 D14 Control group (female bacteriophage) 0.40 0.45 0.60 0.65 0.75 0.80 Experimental group (bacteriophage administration) 0.10 0.05 0 0 0 0 0
  • the bacteriophage Aer-SAP-2 of the present invention is highly effective in the prevention of diseases caused by eromonas salmonidosis.
  • Example 6 Bacteriophage Aer - SAP -2 Eromonas You can live. For diseases caused by bacteria Treatment example
  • the therapeutic effect of bacteriophage Aer-SAP-2 on diseases caused by eromonas salmonididae was investigated.
  • 40 rabbits (average weight: 23.6 g, average length: 15.8 cm) were divided into two groups and divided into two groups.
  • the ambient environment of the water tank was controlled, and the temperature of the laboratory with the water tank was kept constant.
  • Feeds contaminated with eromonas salmonidia were fed twice a day in a conventional feed feeding manner at a level of 1 ⁇ 10 8 cfu / g for 3 days from the 5th day after the start of the experiment. From the last day of contaminated feed, eromonas salmonididae were identified in both tanks with clinical symptoms.
  • the rainbow trout of the experimental group included bacteriophage Aer-SAP-2 from the day after the contaminated feeding of eromonas salmonidida for 3 days (the 8th day after the start of the test) 8 pfu / g) were fed according to the conventional feed feeding method.
  • the rainbow trout of the control group (bacteriophage MIT) received feeds of the same composition without bacteriophage Aer-SAP-2 in the same manner.
  • the incidence of infestation was examined in all test animals on a daily basis.
  • the incidence of incontinence caused by eromonas salmonidida was measured by measuring the ulcer size of the body surface as in Example 5. The results are shown in Table 3.
  • Body size ulcer size measurement (average) US score (mean) date D8 D9 D10 D11 D12 D13 D14 Control group (female bacteriophage) 0.95 1.20 1.45 1.50 1.60 1.55 1.60 Experimental group (bacteriophage administration) 0.95 0.85 0.40 0.30 0.20 0.15 0.10
  • the bacteriophage Aer-SAP-2 of the present invention is very effective for the treatment of diseases caused by eromonas salmonidosis.
  • the feed additive was prepared so that the bacteriophage Aer-SAP-2 contained 1 x 10 8 pfu of bacteriophage Aer-SAP-2 per gram of feed additive.
  • the feed additives were prepared by adding maltodextrin to the bacteriophage solution (50%, w / v) followed by lyophilization. And finally pulverized into a fine powder form.
  • the drying process during the manufacturing process may be replaced by vacuum drying, warm drying, or drying at room temperature.
  • a feed additive without bacteriophage was also prepared by using the buffer (Buffer; 10 mM Tris-HCl, 10 mM MgSO 4 , 0.1% Gelatin, pH 8.0) used in the preparation of the bacteriophage solution instead of the bacteriophage .
  • Buffer 10 mM Tris-HCl, 10 mM MgSO 4 , 0.1% Gelatin, pH 8.0
  • Each of the two feed additives was mixed with a 250 - fold amount of raw fish to produce two final feeds.
  • the bath preparation was prepared as follows. Bacteriophage Aer-SAP-2 solution was used to prepare a bathing agent so that 1 ⁇ 10 8 pfu of bacteriophage Aer-SAP-2 per 1 ml of bath was contained.
  • the manufacturing method of the bathing agent is such that the bacteriophage Aer-SAP-2 solution is added so as to contain 1 ⁇ 10 8 pfu of bacteriophage Aer-SAP-2 per 1 ml of the buffer used for producing the bacteriophage solution, Respectively.
  • the buffer solution used in the preparation of the bacteriophage solution was used as the non-bacteriophage-free bath solution.
  • the two bath preparations thus prepared were diluted with water at a volume ratio of 1,000 times and used as a final bathing agent.
  • Example 7 and Example 8 Using the feeds prepared in Example 7 and Example 8, and a bathing agent, the improvement of the specification results in rainbow trout breeding was investigated. In particular, the survey was conducted in terms of mortality.
  • a total of 200 rainbow trout were divided into two groups of 100 rats divided into two groups (feed-fed group-A, bath-treated group-B) for four weeks. Each group was divided into small groups consisting of 50 animals. Each subgroup was divided into small group (small group-1) with bacteriophage Aer-SAP-2 and small group (small group -2) without bacteriophage.
  • the rainbow trout, which was subject to the test was a 5 - week - old rainbow trout (average weight: 23.8 g, average length: 15.9 cm).
  • Rainbow trout of each test group were kept in separate tanks at regular intervals. Each subgroup is identified and named as shown in Table 4 below.
  • Subgroup classification and display in the rainbow trout specimen test apply Classification and display of small groups Application of bacteriophage Aer-SAP-2 Bacteriophage not applied Group fed with feed A-1 A-2 A group treated with bath B-1 B-2
  • Example 7 In the case of feed feeding, the feed prepared in Example 7 was fed according to a conventional feed feeding method according to the classification of Table 4, and in the case of the bath treatment, the feed prepared in accordance with the preparation method of bath preparation described in Example 8 A bath agent was treated according to a conventional bath bath treatment method in which a fish body was immersed in a diluting solution of a bath agent according to Table 4. The results are shown in Table 5.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un bactériophage de Myoviridae Aer-SAP-2 (numéro d'accès KCTC 12909BP), isolé à partir de milieu naturel, ayant la capacité de tuer des bactéries Aeromonas salmonicida et un génome représenté par SEQ ID NO: 1, et un procédé de prévention ou de traitement d'une maladie causée par des bactéries Aeromonas salmonicida au moyen d'une composition contenant ledit bactériophage en tant que substance active.
PCT/KR2018/009229 2017-08-22 2018-08-10 Nouveau bactériophage d'aeromonas salmonicida aer-sap-2 et son utilisation dans l'inhibition de la prolifération d'aeromonas salmonicida Ceased WO2019039781A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0105842 2017-08-22
KR1020170105842A KR101875565B1 (ko) 2017-08-22 2017-08-22 신규한 에로모나스 살모니시다 박테리오파지 Ａｅｒ-ＳＡＰ-2 및 이의 에로모나스 살모니시다 균 증식 억제 용도

Publications (2)

Publication Number Publication Date
WO2019039781A2 true WO2019039781A2 (fr) 2019-02-28
WO2019039781A3 WO2019039781A3 (fr) 2019-06-27

Family

ID=62920837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009229 Ceased WO2019039781A2 (fr) 2017-08-22 2018-08-10 Nouveau bactériophage d'aeromonas salmonicida aer-sap-2 et son utilisation dans l'inhibition de la prolifération d'aeromonas salmonicida

Country Status (2)

Country Link
KR (1) KR101875565B1 (fr)
WO (1) WO2019039781A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875565B1 (ko) * 2017-08-22 2018-07-06 주식회사 인트론바이오테크놀로지 신규한 에로모나스 살모니시다 박테리오파지 Ａｅｒ-ＳＡＰ-2 및 이의 에로모나스 살모니시다 균 증식 억제 용도
CN110129279B (zh) * 2019-04-24 2022-02-18 昆明理工大学 一种粪肠球菌噬菌体及其分离、纯化、富集和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101329639B1 (ko) * 2012-06-04 2013-11-14 주식회사 씨티씨바이오 신규한 파지 ａｓｐ-1 및 이의 아에로모나스 살모니시다 증식 억제 용도
KR101723827B1 (ko) * 2015-10-28 2017-04-06 주식회사 인트론바이오테크놀로지 신규한 에로모나스 살모니시다 박테리오파지 Aer-SAP-1 및 이의 에로모나스 살모니시다 균 증식 억제 용도
KR101875565B1 (ko) * 2017-08-22 2018-07-06 주식회사 인트론바이오테크놀로지 신규한 에로모나스 살모니시다 박테리오파지 Ａｅｒ-ＳＡＰ-2 및 이의 에로모나스 살모니시다 균 증식 억제 용도

Also Published As

Publication number Publication date
KR101875565B1 (ko) 2018-07-06
WO2019039781A3 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
WO2016108536A1 (fr) Nouveau bactériophage de clostridium perfringens clo-pep-1 et son utilisation pour l'inhibition de la prolifération de clostridium perfringens
WO2016108540A1 (fr) Nouveau bactériophage entéropathogène esc-chp -2 de e. coli et son utilisation pour inhiber la prolifération de e. coli entéropathogène
WO2016108541A1 (fr) Nouveau bactériophage esc-cop-1 contre l'e. coli de type f18 productrice de shigatoxine et utilisation de ce dernier pour inhiber la prolifération de l'e. coli de type f18 productrice de shigatoxine
WO2016108538A1 (fr) Nouveau bactériophage e. coli entérohémorragique esc-chp-1 et son utilisation pour inhiber la prolifération de e. coli entérohémorragique
WO2016114517A1 (fr) Nouveau bactériophage lactococcus garvieae lac-gap-1 et son utilisation dans la suppression de la prolifération de bactéries lactococcus garvieae
WO2016108542A1 (fr) Nouveau bactériophage des souches d'e. coli entéro-invasive esc-4-cop et son utilisation dans l'inhibition de la prolifération des souches d'e. coli entéro-invasive
WO2017111306A1 (fr) Nouveau bactériophage de pasteurella multocida pas-mup-1 et son utilisation pour inhiber la prolifération de pasteurella multocida
WO2016126009A1 (fr) Nouveau bactériophage edw-tap-1 de l'edwardsiella tarda et utilisation associée pour inhiber la prolifération de l'edwardsiella tarda
WO2018101594A1 (fr) Bactériophage esc-cop-7 d'escherichia coli et utilisation correspondante pour supprimer la prolifération d'escherichia coli pathogène
WO2018155812A1 (fr) Nouveau bactériophage ent-fap-4 d'enterococcus faecium et son utilisation pour inhiber la prolifération d'enterococcus faecium
WO2020013451A1 (fr) Bactériophage d'e coli esc-cop-14 et son utilisation pour inhiber la croissance d'e. coli pathogène
WO2018155814A1 (fr) Nouveau bactériophage de clostridium perfringens clo-pep-2 et son utilisation pour inhiber la prolifération de clostridium perfringens
WO2017111305A1 (fr) Nouveau bactériophage de vibrio parahaemolyticus vib-pap-2 et son utilisation pour inhiber la prolifération de vibrio parahaemolyticus
WO2017217726A1 (fr) Nouveau bactériophage vibrio parahaemolyticus vib-pap-5 et son utilisation en vue de supprimer la prolifération des bactéries vibrio parahaemolyticus
WO2018151416A1 (fr) Nouveau bactériophage de pseudomonas aeruginosa (pse-aep-3) et son utilisation afin d'inhiber la prolifération de pseudomonas aeruginosa
WO2017073916A1 (fr) Nouveaux bactériophages aer-sap-1 actifs sur aeromonas salmonicida et leur utilisation pour inhiber la prolifération de aeromonas salmonicida
WO2017111304A1 (fr) Nouveau bactériophage de vibrio parahaemolyticus vib-pap-1 et son utilisation pour inhiber la prolifération de vibrio parahaemolyticus
WO2018208001A1 (fr) Nouveau bactériophage de vibrio parahaemolyticus vib-pap-7 et son utilisation pour inhiber la prolifération de bactéries vibrio parahaemolyticus
WO2018236085A1 (fr) Nouveau bactériophage d'aeromonas hydrophila aer-hyp-1 et son utilisation pour inhiber la croissance d'aeromonas hydrophila
WO2018151417A1 (fr) Nouveau bactériophage pse-aep-4 de pseudomonas aeruginosa et son utilisation dans l'inhibition de la prolifération de pseudomonas aeruginosa
WO2019235782A1 (fr) Nouveau bactériophage de streptococcus suis str-sup-2 et son utilisation pour inhiber la prolifération de souches de streptococcus suis
WO2019235781A1 (fr) Nouveau bactériophage de streptococcus suis str-sup-1 et son utilisation dans l'inhibition de la prolifération de la bactérie streptococcus suis
WO2019039781A2 (fr) Nouveau bactériophage d'aeromonas salmonicida aer-sap-2 et son utilisation dans l'inhibition de la prolifération d'aeromonas salmonicida
WO2013035906A1 (fr) Méthode de prévention et de traitement d'une infection par salmonella typhimurium
WO2018236086A2 (fr) Nouveau bactériophage aeromonas hydrophila aer-hyp-2 et son utilisation dans la prévention de la prolifération de aeromonas hydrophila

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18847983

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18847983

Country of ref document: EP

Kind code of ref document: A2